| abstract |
Provided are: a drug for treating and/or preventing FGFR3 diseases, said drug comprising an HMG-CoA reductase inhibitor as an active ingredient; a method for treating and/or preventing FGFR3 diseases, said method comprising administering an HMG-CoA reductase inhibitor; use of an HMG-CoA reductase inhibitor in producing a drug for treating and/or preventing FGFR3 diseases; and a method for screening a therapeutic agent and/or prophylactic agent for FGFR3 diseases. |